排序方式： 共有5条查询结果，搜索用时 15 毫秒
1
1.
INTRODUCTION In cancer patients, tumor immunity is generally impaired. However, tumor immunity may occur in-vivo as circulating tumor-specific antibodies, with cytotoxic T lymphocytes (CTLs) having been identi- fied in cancer patients (Disis et al., 1997; Albert et al., 1998) suggesting that effective anti-tumor responses may be elicited through immunotherapeutic strategies. In recent years, a number of clinical trials have proved the safety and feasibility of using human dendritic cell… 相似文献
2.
INTRODUCTION With the enormous progress in tumor immu-nology,immunotherapy has reached an exciting phase in its evolution for the treatment of cancer(Hart,2005;Onji and Akbar,2005).Although an effective immunotherapeutic regimen has yet not been dem-onstrated in the clinical setting and the ultimate role of immunotherapy in the treatment of glioma is still unknown,the potential for immunotherapy as an adjunct to the current treatment of gliomas is now based on solid evidence(Yu et al.,20… 相似文献
3.
Gallbladder cancer has a poor outcome because of its anatomy and location. Often, the diagnosis is made very late due to its silent course. Post-operated cases do respond to chemotherapy but the survival is counted in months and the quality of life is further hampered due to toxicity of drugs. Immunotherapy holds good promise in non-responding cancers treated by conventional chemotherapeutic agents. Among various therapies, dendritic cell therapy is growing at rapid pace due to its acceptable rationale. It has been utilized in treating successfully resected stage Ill （T2, N1, M0） gallbladder cancer in one of our patients. A 48 years old lady treated with this therapy is free of metastasis with ten doses of autologous dendritic cell vaccine constructed by utilizing resected tumor lysate antigen. She has received ten doses of therapy in 14 months of her treatment. This therapy has proven to be safe and without apparent side effects. The positive clinical response obtained supports that autologous dendritic cell-based immunotherapy is a promising therapeutic approach for refractory gallbladder cancers. 相似文献
4.
5.
Malignant gliomas are the most devastating tumors in clinical practice and nave poorest survival, Immunological treatment of such patients may likely increase the survival and quality of life. Dendritic cells （DCs）, most potent antigen presenting cells in combination with oral chemotherapeutic agents may be tried for patients giving consent to such treatment. We have successfully combined the two therapies in an adult male patient who was on downhill course after being operated on once with post operation chemotherapy and radiotherapy for glioma in the left parietal area. He received five dendritic cell therapy vaccines in combination with oral chemotherapy and responded dramatically having near normal quality of life for an additional five months with this regime, increasing the survival after operation to 11 months. This therapy is continuing with radiological betterment of the lesion. The DCs are matured with antigen extracted from wax embedded tissue at 6th day of culture. We feel that the treatment can be given to more number of patients to establish its efficacy for the dreaded cancer glioblastoma multiforme. 相似文献
1